Similarly, Yildiz et al. observed that a high expression level of MSLN in advanced serous ovarian cancers was associated with a poor prognosis and with worse platinum sensitivity in the advanced stage [38]. The gene discussed is MSLN; the disease is ovarian serous adenocarcinoma.